FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to a method of treating cytomegalovirus infection in pregnant women. Method involves using Genferon® Light. If CMV DNA is positive in vagina and/or in any viral load of cop/ml in blood, Genferon® Light is used rectum in amount of 250,000 ME as follows: 1 suppository 2 times day for 14 days, then 1 suppository 3 times a week (Monday, Wednesday, Friday) until complete virus elimination from vagina and blood, only if positive CMV DNA from vagina is used Genferon® Light is used vaginally according to the above scheme until complete virus elimination from vagina.
EFFECT: disclosed method enables higher clinical reliability of cytomegaloviral infection in pregnant women.
1 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING GENERALIZED CYTOMEGALOVIRUS INFECTION IN CHILDREN OF EARLY AGE | 2015 |
|
RU2602953C1 |
| METHOD OF ESTIMATING EFFICIENCY OF THERAPY OF CHRONIC CYTOMEGALOVIRAL INFECTION IN CHILDREN | 2014 |
|
RU2566074C1 |
| METHOD OF TREATING CONJUGATION HYPERBILIRUBINEMIA IN INFANTS | 2014 |
|
RU2570479C1 |
| METHOD OF TREATING REACTIVATED FORM OF UROGENITAL CYTOMEGALOVIRAL INFECTION IN FEMALES OF REPRODUCTIVE AGE | 2013 |
|
RU2513474C1 |
| METHOD FOR NON-SPECIFIC PREVENTION OF ACUTE RESPIRATORY INFECTIONS IN INFANTS WITH CHRONIC HERPETIC INFECTIONS - CYTOMEGALOVIRUS, EPSTEIN-BARR VIRUS | 2020 |
|
RU2750522C1 |
| METHOD FOR ASSESSMENT OF ACTIVITY OF INFECTION CAUSED BY HERPES TYPE 4, 5 AND 6 IN CHILDREN | 2016 |
|
RU2639593C1 |
| METHOD FOR PREDICTION OF MANIFESTED FORM OF CONGENITAL CYTOMEGALOVIRAL INFECTION WITH CNS DAMAGE IN NEWBORN | 2024 |
|
RU2839129C1 |
| METHOD FOR RESTORING AND KEEPING FAMILY HEALTH | 2002 |
|
RU2230558C2 |
| DIAGNOSTIC TECHNIQUE FOR CONGENITAL VIRAL FOETAL DISEASE | 2019 |
|
RU2728925C1 |
| METHOD FOR PREDICTION OF DEVELOPING CONGENITAL CYTOMEGALOVIRUS INFECTION IN NEWBORNS | 2023 |
|
RU2822967C1 |
